These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 3611825)

  • 21. [Adult kala-azar revealed by jaundice and associated with various immunological disorders (author's transl)].
    Barrier J; Grolleau JY; Le Bodic MF; Marjolet M; Schneebeli S; Buzelin F; Peltier P; Hardy M
    Gastroenterol Clin Biol; 1981 Oct; 5(10):847-52. PubMed ID: 7297801
    [No Abstract]   [Full Text] [Related]  

  • 22. Splenectomy in kala-azar.
    Rees PH; Kager PA; Kyambi JM; Ayim EN; Bhatt KM; Schattenkerk JK
    Trop Geogr Med; 1984 Sep; 36(3):285-92. PubMed ID: 6506208
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunological studies in kala-azar (case report).
    Narayanan K; Rajagopalan P; Raina V; Kumar R; Malaviya AN
    J Assoc Physicians India; 1981 Feb; 29(2):169-72. PubMed ID: 7263604
    [No Abstract]   [Full Text] [Related]  

  • 24. Widal reaction in Kala-azar.
    Singh UK; Sinha RK; Sharma VK
    Indian Pediatr; 1995 Jun; 32(6):680-3. PubMed ID: 8613339
    [No Abstract]   [Full Text] [Related]  

  • 25. Immunity in kala-azar.
    MANSON-BAHR PE
    Trans R Soc Trop Med Hyg; 1961 Nov; 55():550-5. PubMed ID: 14469435
    [No Abstract]   [Full Text] [Related]  

  • 26. Recurrence of kala-azar associated with post-kala-azar dermal leishmaniasis.
    Sen Gupta PC; Mukherjee AM
    J Indian Med Assoc; 1968 Jan; 50(1):1-5 passim. PubMed ID: 5668350
    [No Abstract]   [Full Text] [Related]  

  • 27. Post-kala-azar dermal leishmaniasis.
    Baghestani S; Handjani F; Sodeifi M; Kumar PV
    Eur J Dermatol; 1998 Jun; 8(4):277-9. PubMed ID: 9649686
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Visceral leishmaniasis (kala-azar) in Fars Province, Iran: study of 130 cases.
    Hashemi-Nasab A; Zadeh-Shirazi H
    J Trop Med Hyg; 1980 Jun; 83(3):119-22. PubMed ID: 7401218
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunoprophylaxis against kala-azar. I. Experimental L. donovani infection in golden hamsters.
    Jalees S; Topa PK; Sharma RR; Jaleel S; Joshi MC; Hussain QZ
    J Commun Dis; 1981 Dec; 13(4):273-80. PubMed ID: 7348725
    [No Abstract]   [Full Text] [Related]  

  • 30. [Consumption coagulopathy complicating Mediterranean kala-azar in an adult].
    Hauteville D; Verdier M; Martin J; Pierron JR; Abgrall J
    Sem Hop; 1982 Sep; 58(35):2019-20. PubMed ID: 6293090
    [No Abstract]   [Full Text] [Related]  

  • 31. [Surveillance of kala-azar following preliminary eradication].
    Shao QF
    Zhonghua Liu Xing Bing Xue Za Zhi; 1982 Feb; 3(1):35-7. PubMed ID: 7185432
    [No Abstract]   [Full Text] [Related]  

  • 32. Changes in age incidence of kala-azar in India.
    Basu D; Mallik KK
    Indian J Public Health; 1995; 39(1):26. PubMed ID: 8690477
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Post-kala-azar dermal leishmaniasis and borderline tuberculoid leprosy.
    Walker SL; Kahawita I
    Br J Dermatol; 2008 Feb; 158(2):417. PubMed ID: 18047513
    [No Abstract]   [Full Text] [Related]  

  • 34. [Comparative study of fluorescent antibody indirect reactions in Chagas' disease, mucocutaneous leishmaniasis and kala-azar using various Leishmania and Trypanosoma antigens].
    Nery-Guimarães F; Lage HA; Venancio IA; Grynberg NF
    Hospital (Rio J); 1969 May; 75(5):1811-25. PubMed ID: 4979318
    [No Abstract]   [Full Text] [Related]  

  • 35. Prevalence of visceral leishmaniasis associated with the behaviors of the people in rural areas.
    Shah H
    JNMA J Nepal Med Assoc; 2005; 44(160):116-20. PubMed ID: 16751812
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of renal function in human visceral leishmaniasis (kala-azar): a prospective study on 50 patients from Brazil.
    Lima Verde FA; Lima Verde FA; Lima Verde IA; Silva Junior GB; Daher EF; Lima Verde EM
    J Nephrol; 2007; 20(4):430-6. PubMed ID: 17879209
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lesional T-cell subset in post-kala-azar dermal leishmaniasis.
    Rathi SK; Pandhi RK; Chopra P; Khanna N
    Int J Dermatol; 2005 Jan; 44(1):12-3. PubMed ID: 15663651
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunopathology of post kala-azar dermal leishmaniasis (PKDL): T-cell phenotypes and cytokine profile.
    Ismail A; El Hassan AM; Kemp K; Gasim S; Kadaru AE; Moller T; Kharazmi A; Theander TG
    J Pathol; 1999 Dec; 189(4):615-22. PubMed ID: 10629566
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Post-kala-azar dermal leishmaniasis (PKDL): the first case report from Nepal.
    Karki P; Koirala S; Parija SC; Sethi M; Das ML
    Southeast Asian J Trop Med Public Health; 2003 Mar; 34(1):22-3. PubMed ID: 12971510
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gamma interferon in the treatment of Kala-azar and other forms of Leishmaniasis.
    Sundar S; Murray HW
    J Assoc Physicians India; 1995 May; 43(5):348-50. PubMed ID: 9081967
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.